retatrutide glp-1 Obesity is expected to affect nearly a quarter of the world population by 2035. Retatrutide, an investigational GIP, GLP-1, and GCG receptor agonist, holds promise for weight reduction in adults. New Retatrutide vs Semaglutide and Tirzepatide:
Pay in 4 interest-free payments of $6.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22

























